Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
- Status
- COMPLETED
- Phase
- PHASE2
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of BMS-986158 in Subjects With Select Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2